Progyny, Inc. is a benefits management company that provides fertility, family building, and women's health benefits solutions in the United States. Its offerings include fertility benefits with differentiated plan design and a smart cycle treatment bundle, personalized concierge-style member support, and a selective network of fertility specialists. The company also provides Progyny Rx, an integrated pharmacy benefits solution, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. Additionally, it offers an assistance service program covering adoption, surrogacy, doula, and travel reimbursement. Formerly known as Auxogyn, Inc., it changed its name to Progyny, Inc. in 2015, was incorporated in 2008, and is headquartered in New York, New York.
Health insurance providers reported a strong second quarter, with revenues beating analysts' consensus estimates by 2.8% while next quarter's revenue guidance came in 1.7% below expectations. Clover Health reported revenues of $743.2 million, up 55.6% year on year, exceeding analysts' expectations by 2%, and its stock is up 1.9% since reporting. CVS Health posted revenues of $106.1 billion, up 7.3% year on year, outperforming analysts' expectations by 6.7%, but its stock is down 10.2% since reporting. Progyny delivered the weakest guidance update among its peers, with revenues of $350.5 million, up 5.3% year on year, and its stock is down 15.3% since the results. On average, share prices of the 12 health insurance providers stocks tracked are down 6.2% since the latest earnings results.
Progyny reported second-quarter revenue and profit above Wall Street expectations but lowered its full-year revenue guidance, sending shares down. Revenue was $350.5 million versus analyst estimates of $348.5 million, a 5.3% year-on-year increase, while adjusted EPS of $0.55 beat estimates by 6.2%. The company cut full-year revenue guidance to $1.37 billion at the midpoint from $1.39 billion, a 0.9% decrease, and EBITDA guidance of $236.5 million came in below analyst estimates of $239.1 million. Management attributed flat sales volumes to more pronounced summer seasonality and said early client commitments are ahead of last year.
Progyny Stock Drops After Conservative Q3 Guidance Despite Q2 Beat
Progyny shares fell 6% after the fertility benefits company reported second-quarter results and issued third-quarter revenue guidance of 7% to 11% growth that disappointed investors. Second-quarter sales rose 5%, or 11% excluding a large client departure, and adjusted earnings per share jumped 15%, beating Wall Street expectations. Gross profit margins expanded 180 basis points, and the average number of covered members grew 7% to 7.2 million. Management highlighted the new Progyny Select offering, a pooled risk model targeting smaller employers with 100 or more employees, as a potential growth driver. The company also noted near-100% client retention and share count reductions of 8% annually over the past three years.
Biotech Stocks Hit 52-Week Highs on Clinical Results and New Initiatives
Several biotech stocks reached 52-week highs on July 14, 2026, driven by positive clinical data and new program launches. Hemab Therapeutics hit $42.03 after reporting encouraging Phase 2 results for its Von Willebrand's disease candidate HMB-002 and unveiling a new drug candidate, HMB-003, for heavy menstrual bleeding. Alamar Biosciences touched $29.43 following a partnership with U.S. research universities to launch a national proteomics initiative using its NULISAseq Neuro 220 panel for Alzheimer's biomarker discovery. Progyny rose over 4% to $32, with the company projecting full-year 2026 revenue between $1.365 billion and $1.405 billion, a 5.9% to 9% increase. 10x Genomics closed at a 52-week high of $43.98 after recent collaborations, including a bladder cancer diagnostic project with Cleveland Clinic, and expects 2026 revenue of $600 million to $625 million. Viemed Healthcare peaked at $12.61, forecasting net revenues of $312 million to $320 million for 2026.
Analysts recommend caution on Progyny following its first-quarter earnings, citing weak sales volumes, limited scale, and stagnant adjusted operating margins. Units sold reached 15,647 in the latest quarter, with two-year average annual growth of just 4.5%, lagging the sector and signaling waning demand. With trailing 12-month revenue of $1.29 billion, the company's small size hampers its ability to build trust in the resource-intensive healthcare industry. Adjusted operating margin has remained flat over the past two years at 16.7%, raising concerns about expense management despite revenue growth. The stock trades at 14.8 times forward earnings, or $31.10 per share, which analysts view as fair but offering limited upside.
Truist raises Progyny price target to $33 after management meetings
Truist raised its price target on Progyny to $33 from $30 while maintaining a Buy rating following meetings with the company's management team. The firm cited Progyny's differentiated fertility benefits model, superior clinical outcomes, and comprehensive member services as key strengths. Earlier, BofA increased its target to $31 from $29, pointing to favorable fertility prescription trends and rising Google search activity that suggest utilization is tracking ahead of expectations. Progyny specializes in fertility, family-building, and women's health benefits management, with a projected five-year EPS growth rate of 40.83%.
UnitedHealth leads health insurers with strong Q1 earnings beat
UnitedHealth reported first-quarter revenues of $111.7 billion, up 2% year on year and exceeding analysts' expectations by 1.7%, with an impressive beat of full-year EPS guidance estimates. Among the 12 health insurance providers tracked, CVS Health delivered the biggest analyst estimate beat with revenues of $100.4 billion, up 6.2% year on year, while Progyny achieved the highest guidance raise and highest full-year guidance raise among its peers. Cencora fell short of expectations with revenues of $78.36 billion, and Molina Healthcare met revenue estimates but issued full-year revenue guidance that missed analysts' expectations. Overall, the group beat revenue consensus estimates by 1.4% and share prices have risen 41.9% on average since the latest earnings results.
Health Insurance Providers Stocks Q1 In Review: Alignment Healthcare Vs Peers
Alignment Healthcare reported first-quarter revenues of $1.24 billion, up 33.3% year on year, exceeding analysts' expectations by 1.3%. The company added 48,500 customers to reach a total of 284,800, but its EBITDA guidance for the next quarter missed analysts' expectations, making it the weakest guidance update among the 12 health insurance providers stocks tracked. CVS Health posted the biggest analyst estimate beat with revenues of $100.4 billion, up 6.2% year on year, while Cencora had the weakest quarter with revenues of $78.36 billion, falling short of expectations by 3.9%. Oscar Health reported revenues of $4.65 billion, up 52.6% year on year, but lagged analysts' expectations by 5.7%, and Progyny reported revenues of $328.5 million, up 1.4% year on year, surpassing expectations by 0.7% and achieving the highest guidance raise among its peers. Overall, the group's revenues beat consensus estimates by 1.4%, and share prices have risen 36.3% on average since the latest earnings results.
StockStory flags Chegg, Progyny, and Forestar Group as value stocks facing uphill battles
StockStory identified Chegg, Progyny, and Forestar Group as three value stocks that may be value traps. Chegg, trading at 3.7 times forward EV/EBITDA, has seen services subscribers decline 23.3% annually over two years and falling EBITDA profits. Progyny, at 13.1 times forward P/E, faces soft demand with disappointing unit sales and an unchanged adjusted operating margin. Forestar Group, at 10.9 times forward P/E, posted annual revenue growth of 8.8% over five years, below sector standards, and shows eroding returns on capital.
Progyny CFO Mark Livingston sold 8,275 shares under a pre-arranged trading plan
Progyny Chief Financial Officer Mark Livingston sold 8,275 shares of common stock in an open-market transaction on May 20, 2026, at $25.50 per share, for a total value of $211,000. The sale represented 9.47% of his direct holdings, leaving him with 79,063 shares worth approximately $2.03 million based on that day's closing price. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025, and no indirect or derivative holdings were affected. Progyny, which provides fertility and family-building benefits, reported trailing-twelve-month revenue of $1.29 billion and net income of $67.69 million, and has projected 2026 revenue growth of 6% to 9%, or 10% to 13% excluding a lost major client.
PGNY · Capital · Negative CFO sold 8,275 shares under a pre-arranged plan, representing 9.47% of his direct holdings, which may signal insider sentiment.
StockStory picks Sanmina as a Russell 2000 buy, flags Genco and Progyny as sells
StockStory highlights Sanmina as a Russell 2000 stock for long-term investors while recommending selling Genco and Progyny. Sanmina, an electronics manufacturing services company with a $13.24 billion market cap, posted 19.3% annual revenue growth over the past two years and has a 29.3% growth outlook for the next 12 months, with earnings per share boosted by share buybacks. Genco, a dry bulk shipping firm valued at $1.03 billion, saw earnings per share fall 32.6% annually over two years and its free cash flow margin shrink by 75.7 percentage points over five years. Progyny, a fertility benefits provider with a $2.01 billion market cap, showed underwhelming unit sales and static adjusted operating margins on a $1.29 billion revenue base.
CVS Health Leads Health Insurer Q1 Earnings with Strongest Beat
CVS Health posted the strongest first-quarter results among 12 tracked health insurance providers, with revenues of $100.4 billion beating analyst expectations by 6.3%. The group overall exceeded revenue consensus by 1.4%, while next-quarter guidance was in line. Centene also outperformed, reporting $49.94 billion in revenue and topping estimates by 6.2%, while Cencora lagged with $78.36 billion, missing forecasts by 3.9%. Progyny and Alignment Healthcare rounded out the cohort, with Progyny raising full-year guidance the most among peers and Alignment adding 48,500 customers to reach 284,800 total members.
United States